Last week in context

six peptides cleared the fda panel — aod-9604 wasn't on the docket

The FDA's Pharmacy Compounding Advisory Committee wrapped a two-day session on July 24, 2026, and the headline from those hearings was six: BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon each received positive committee votes for inclusion on the 503A bulk drug substances list. The [FDA's official meeting page](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) documents the full docket. AOD-9604 was not on it — and that absence is not a scheduling gap. The FDA's advisory committee had already reviewed AOD-9604 on December 4, 2024, and the staff evaluation found the criteria weighed against inclusion on multiple counts: inadequate physicochemical characterization, immunogenicity concerns from impurities and aggregates, no clinical effectiveness data for any approved use, and no published human exposure data for the proposed subcutaneous and topical routes. By the time July's docket was assembled, AOD-9604's nomination had been withdrawn entirely. TikTok, meanwhile, is running active dosing guides, reconstitution protocols, and stack recommendations for AOD-9604 in August 2026 as though none of that regulatory history exists. The gap between the peptide's legal standing and the internet's confidence in it has never been wider.

The actual biology

aod-9604 is a c-terminal fragment of growth hormone — designed to isolate lipolysis from the rest of gh

Growth hormone is a 191-amino-acid protein with multiple biological effects, including growth signaling and the capacity to mobilize fat from stored adipose tissue. The observation that drove AOD-9604's development was that different regions of the GH molecule appear responsible for different functions. The C-terminal fragment — amino acids 176 through 191 — seemed to concentrate much of the lipolytic activity without carrying the growth-promoting and insulin-disrupting signaling associated with the rest of the molecule. Metabolic Pharmaceuticals developed AOD-9604 as a fragment specifically designed to isolate that fat-mobilizing signal. The theoretical appeal was direct: a peptide that targets fat metabolism the way growth hormone does, without the insulin resistance concerns, the potential for cell proliferation signaling, or the acromegaly-adjacent effects that accompany sustained exogenous GH use. The [PubMed literature on AOD-9604](https://pubmed.ncbi.nlm.nih.gov/?term=AOD-9604) traces the mechanistic research through beta-3 adrenoreceptor pathways, adipocyte effects, and a later line of cartilage research that emerged after the obesity program closed. The mechanism is biologically coherent. Coherent mechanism and clinically proven outcome are different things — and the distance between those two is precisely what the Phase 2b trial was designed to measure.

The wellness pitch

the claim promises gh-style fat loss without gh's side effects — that framing is carrying weight it shouldn't

AOD-9604's positioning in wellness culture is precisely what makes it durable despite a clinical development termination: it is framed as a fat-loss peptide without the drawbacks of every alternative on the market. Not exogenous growth hormone, which raises insulin resistance concerns and long-term tissue questions. Not a GLP-1 drug, which causes nausea and is now under active FDA enforcement against unlicensed compounders. Not a stimulant. AOD-9604 occupies the space where 'targeted and specific' meets 'no real side effects known' — a peptide that supposedly signals fat cells directly without disrupting broader hormonal architecture. Active TikTok content in August 2026 includes stacking protocols that pair it with tesamorelin and sermorelin as part of body composition protocols, with creators describing it as a clinically studied compound. That description is accurate. What the clinical study found is the part that rarely makes it into the content.

What the data says

six trials and 900-plus participants — and the pivotal phase 2b still couldn't beat placebo

AOD-9604 is unusual in the research-peptide world because it completed human efficacy trials — real randomized controlled studies, not forum reports or anecdotal accounts. Metabolic Pharmaceuticals ran six human trials involving more than 900 participants, moving through dose-finding and mechanistic phases into a pivotal Phase 2b. That trial enrolled more than 500 obese adults across multiple dose levels and ran for 24 weeks. The [published AOD-9604 obesity trial literature on PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=AOD-9604+obesity+clinical+trial) documents the trajectory: early dose-finding studies showed some signal at specific doses — roughly 2.6 kg weight loss at one dose level versus 0.8 kg for placebo — but the Phase 2b results failed to separate from placebo at the primary efficacy endpoint. Development was terminated in 2007. The FDA's December 2024 PCAC review cited the complete absence of clinical effectiveness data for any approved use as a key criterion weighing against 503A inclusion. [ClinicalTrials.gov](https://clinicaltrials.gov/search?term=AOD-9604) shows the registered trial history. The [FDA's bulk drug substances safety framework](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) defines the criteria the committee applied. Research interest after 2007 shifted toward a potential cartilage repair indication — preclinical work continues on that question — but the cartilage research does not alter the primary endpoint result from the obesity trials.

Early human — PeptideFactCheck stance

real trials ran, real result logged — the regulatory withdrawal reflects what the science found

AOD-9604 carries the Early human evidence tier: interesting mechanism and real human trial data, but too early for clinical certainty — and, in this case, a pivotal efficacy trial that came up short. What separates this compound from most in that tier is that the human evidence exists and was specifically tested against the exact claim people make today, and the result was a failed pivotal study. That is a more specific finding than the absence of human trials. The efficacy investigation ran. The Phase 2b did not support the primary endpoint. The developer terminated the program in 2007. The FDA's December 2024 evaluation cited insufficient effectiveness data among multiple characterization concerns, and the 503A nomination was subsequently withdrawn. Six peptides received positive FDA advisory panel recommendations this month. AOD-9604 had already been reviewed, found wanting on the key evidence criteria, and removed from the active docket before July's hearings were assembled. The mechanism is real. The fragment pharmacology is interesting. The cartilage research is ongoing. None of that changes what the pivotal obesity trial found — which is the one piece of information that most TikTok content on AOD-9604 this August is not disclosing.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.